Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia

Marc Poncin,a Gideon Zulu,b Caroline Voute,a Eva Ferreras,c Clara Mbwili Muleya,b Kennedy Malama,b Lorenzo Pezzoli,j Jacob Mufunda,k Hugues Robert,l Florent Uzzeni,l Francisco J Luquero,a Elizabeth Chizemab & Iza Cigleneckia

Objective To describe the implementation and feasibility of an innovative mass vaccination strategy – based on single-dose oral cholera vaccine – to curb a cholera epidemic in a large urban setting.

Method In April 2016, in the early stages of a cholera outbreak in Lusaka, Zambia, the health ministry collaborated with Médecins Sans Frontières and the World Health Organization in organizing a mass vaccination campaign, based on single-dose oral cholera vaccine. Over a period of 17 days, partners mobilized 1700 health ministry staff and community volunteers for community sensitization, social mobilization and vaccination activities in 10 townships. On each day, doses of vaccine were delivered to vaccination sites and administrative coverage was estimated.

Findings Overall, vaccination teams administered 424 100 doses of vaccine to an estimated target population of 578 043, resulting in an estimated administrative coverage of 73.4%. After the campaign, few cholera cases were reported and there was no evidence of the disease spreading within the vaccinated areas. The total cost of the campaign – 2.31 United States dollars (US$) per dose – included the relatively low cost of local delivery – US$ 0.41 per dose.

Conclusion We found that an early and large-scale targeted reactive campaign using a single-dose oral vaccine, organized in response to a cholera epidemic within a large city, to be feasible and appeared effective. While cholera vaccines remain in short supply, the maximization of the number of vaccines in response to a cholera epidemic, by the use of just one dose per member of an at-risk community, should be considered.

Abstracts in العربية, 中文, Français, Русский и Español at the end of each article.

Introduction

The World Health Organization (WHO) has estimated that there are 1.3–4 million cholera cases and 21 000–143 000 cholera-related deaths each year.1 Cholera is a poverty-related disease and large-scale cholera epidemics continue to occur in low-income countries. In 2015, for example, an outbreak that involved approximately 40 000 people affected parts of the Democratic Republic of Congo, Kenya and the United Republic of Tanzania.2 The prevention and control of epidemics are usually based on a multidisciplinary integrated approach that may include community sensitization, intensified epidemiological surveillance, improved access to clean water, hygiene and sanitation and the treatment of confirmed and suspected cases. Recent large-scale cholera outbreaks have shown the limitations of standard response measures and the need for improved strategies.7

The first documented campaign using oral cholera vaccine in a humanitarian context was carried out in 1997, in Uganda.8 Since then, similar preventive vaccinations have been organized in areas considered at risk of a cholera outbreak.4–6 In recent years, increased use of oral cholera vaccine in different settings and mostly in a preventive manner has provided evidence of the feasibility and effectiveness of vaccination campaigns against cholera.7,8 A turning point in the implementation of cholera vaccination campaigns was WHO’s prequalification of the Shanchol oral cholera vaccine in 2011.7 In 2013, under the supervision of the International Coordination Group on Vaccine Provision, a global stockpile of oral cholera vaccine was created to strengthen the capacity for action against cholera in emergency settings.7,8

Timely reactive vaccinations – i.e. vaccinations in response to an existing epidemic – for cholera outbreaks are challenging, because it can take considerable time to identify and report a cholera epidemic and it is hard to predict outbreaks. Other possible challenges are inadequate financial and human resources and inadequate number of doses to target everyone at risk of cholera, especially for a multi-dose campaign.11 While the licensed protocol requires two doses of oral cholera vaccine to be given two weeks apart, the feasibility of such a regimen has been, and remains, limited by the availability of suitable vaccines doses. Given a global shortage of such vaccines, a single-dose strategy, which, given a fixed number of doses, could cover twice as many people as a two-dose regimen, should be considered.12 This strategy was first used under field conditions in 2015, in Juba, the conflict-ravaged capital of South Sudan, when more than 160 000 people were vaccinated in response to a cholera outbreak.11 In a short-term observational study, the effectiveness of a single dose of vaccine in this campaign in Juba was estimated to be 87.3% (95% confidence interval, CI: 70.2–100.0).13 In 2014, a clinical trial in Bangladesh indicated that a single dose of oral cholera vaccine would give...
Cholera is a public-health problem in many areas of Zambia, but is a particular problem in the capital, Lusaka.\textsuperscript{15} Although there were annual cholera epidemics in Zambia between 2003 and 2011, no confirmed cases of the disease were reported in the country in 2012–2015. When, therefore, a few people with the disease were detected in Lusaka in February 2016, general levels of immunity to cholera were assumed to be relatively low in Zambia. At the time, there was concern that there was considerable risk of an imminent major outbreak. The Lusaka District Health Office quickly organized a response according to the national guidelines on cholera control.\textsuperscript{16} In addition, the Zambian Ministry of Health, with support from Médecins Sans Frontières and WHO, implemented a reactive vaccination campaign with the aim of stopping transmission of Vibrio cholerae in Lusaka. In 2016, almost 600 000 people were living in the nine townships of Lusaka that were considered at greatest risk, because they had been the foci of cholera outbreaks in the previous two decades. Given the large target population and the global shortage of appropriate vaccine doses, it was decided to use a single-dose vaccination campaign, rather than a two-dose strategy, and so allow the largest number of vulnerable people to be vaccinated with the doses that were available.

Here we describe the context of the interventions and the decision-making process and we evaluate the feasibility of conducting such a large-scale reactive campaign of cholera vaccination in high-risk and densely-populated urban areas.

Methods

Setting

Lusaka is a fast-growing city with a population of over 2 million people. Between 2003 and 2011, there were annual cholera epidemics, 26 000 cholera cases and 860 cholera-related deaths recorded in the city.\textsuperscript{15} Over this period, Médecins Sans Frontières helped the health ministry to control the cholera outbreaks in the city and record the numbers of people with cholera per township, the seasonal pattern of cholera and assess water and sanitation quality in each township.\textsuperscript{7} Most epidemics recorded in the city since 2003 began in December/January and finished, as the rainy season ended, around April/May.\textsuperscript{17} They started in one or more of nine townships that had particularly poor water supplies and drainage systems.\textsuperscript{17}

On 4 February 2016 – i.e. in epidemiological week 5 of 2016 – a person with cholera was identified in Lusaka. This represented the first confirmed case in the city since 2011. Confirmed and/or suspected cases were identified over the next few days and a cholera outbreak was declared. Laboratory analysis showed that the agent causing this outbreak was V. cholerae O1 El Tor-Ogawa. The number of confirmed and/or suspected cases increased rapidly, from 14 in epidemiological week 9 to 118 in epidemiological week 10 (Fig. 1).

Decision-making and vaccine provision

In early March 2016, the health ministry, fearing an imminent major epidemic, requested the assistance of Médecins Sans Frontières in controlling the epidemic. There were 277 confirmed and/or suspected cholera cases reported on 18 March. Of these cases, 57 were found positive in a rapid diagnostic test for cholera and 25 were confirmed by culture. As a result of these observations, the health ministry, Médecins Sans Frontières and WHO agreed to add vaccination to the standard cholera-control activities that had already been implemented. However, when this agreement was made, the global emergency stockpile of oral cholera vaccine, containing about 1.3 million doses, was far too small to allow Zambia and several other countries with urgent requirements for cholera vaccine to give everyone in at-risk populations two doses. We therefore decided to follow a single-dose vaccination strategy in Lusaka, to cover everyone who was older than one year and lived in a high-risk township, and to consider delivering a second dose later, when more vaccine doses became available. On March 24, the health ministry sent a request to the International Coordination Group, to access 598 131
doses from the emergency stockpile\textsuperscript{1} and they received a positive response five days later. The allocated vaccine was Shanchol (Shantha Biotechnics, Hyderabad, India) and the vaccine doses arrived in Zambia, in two shipments, on 7 and 8 April. Although Shanchol was not registered in Zambia, the health ministry approved its emergency use and facilitated the importation process.

**Target population**

The target population included all individuals older than one year who lived in one of the 10 townships of Lusaka that, in March 2016, were considered high-risk for cholera. Nine townships had the highest attack rates in the epidemics in 2003–2011 and one township had a high incidence of suspected cholera when the vaccine request was sent. To estimate the population of these townships, we combined population projections from the 2010 national census\textsuperscript{19} with other relevant population data (Lusaka City Council, unpublished data, 2016).

**Vaccination strategy**

Vaccination teams implemented a two-phase strategy designed to cover the entire target population within a short period. The first phase involved the setting up of static vaccination sites, which were easy to organize and control, in health facilities or churches or schools. Each static site was covering a circular area, centred on the site, with a maximum radius of 500 m (Fig. 2). Each such site was scheduled to open from 07:00 to 18:00 on each of two to six days, the exact period depending on the turn-out of the target population. We set a vaccination target of each static site to 5500 doses per day, to match the financial and logistical resources that were available.

The second phase comprised a three-day catch-up campaign in which mobile vaccination teams operated, on main roads or in markets or other socially active places, to vaccinate targeted individuals who had failed to attend the static sites.

**Vaccination teams**

Each vaccination team was composed of 23 volunteers and a qualified nurse from the health ministry who acted as team leader. Before the campaign, we organized a half-day training session in each high-risk township. This included a practical exercise in organizing a vaccination site. The team composition was such that, at each vaccination site, two vaccination lines, each run by two vaccinators, two people preparing vials, four recorders filling in cards and one person summarizing the records on a tally sheet, could be formed. Other team members were responsible for crowd control. In an attempt to facilitate the acceptance of the campaign, we selected the team members for each targeted township from the local population. Overall, 989 individuals created 53 teams, 42 at static sites and 11 running the mobile sites. At the height of the activity there were 17 sites working simultaneously.

**Fig. 2.** Estimated administrative coverages in the 10 townships of Lusaka targeted in a mass immunization campaign against cholera, Zambia, 2016

| Township                | Administrative coverage (%) |
|-------------------------|----------------------------|
| George-Soweto           | 60–70                      |
| George                  | 70–80                      |
| New Kanyama             | 80–90                      |
| Old Kanyama             | 90–100                     |
| Kanyama West            | >100                       |
| John Laing Misisi-Kuku  |                           |
| Chawama                 |                           |
| Lusaka City Airport     |                           |
| Bauleni                 |                           |

Note: Data are shown only for the areas targeted in a mass immunization campaign based on single doses of oral cholera vaccine, i.e. Bauleni township in the east of the city and nine other townships in the west.
Social mobilization

In each targeted township, qualified environmental health technicians from the health ministry organized three days of community sensitization and mobilization before the vaccinations began and then continued similar activities for the duration of the campaign. A flyer explaining the characteristics of the vaccine and the dates and locations of the vaccination sites was developed locally and handed out. Vehicles with sound systems were driven around the targeted townships to advertise the vaccinations. Awareness-raisers worked near the vaccination sites. There were another 745 individuals, again a mix of health ministry staff and community volunteers, involved in the social mobilization.

Cold-chain management

The Universal Child Immunization’s Secretariat Office in Lusaka stored the vaccines in a cold room. We distributed the vaccines to vaccination sites, with icepacks, as 1500-dose boxes in their original packaging. The vaccines were used at ambient temperature on the vaccination day. The vaccinators checked the vaccine vial monitor before administering each dose.

Data collection and analysis

Recorders categorized the age of each vaccinee as one to four years, five to 14 years or adult, i.e. at least 15 years, on a tally sheet, but ignored sex. On a daily basis, the recorders compiled the sheets to allow the daily evaluation of administrative coverages to be estimated each day. The estimated coverages were then used to plot a performance map for each targeted township. By rapidly sharing such maps among partners, it was possible to make quick compensations for poor coverage in particular areas, e.g. increasing the duration of the vaccination period at some sites and reinforcement of sensitization activities. We calculated vaccine wastage as the percentage of the number of doses leaving the cold room that, according to the tally sheets, were lost. We expressed cholera attack rates as the numbers of confirmed and/or suspected cases per 10 000 people and as the numbers of confirmed and/or suspected cholera cases that, according to the tally sheets, were reported. In Lusaka, the overall attack rate was 4.89 per 10 000 people. Attack rates were significantly higher among children younger than five years than among older individuals: 5.80 vs 4.71 per 10 000 people (attack rate ratio: 1.23; 95% CI: 1.06–1.42). They were also significantly higher among males than among females: 5.20 vs 4.59 per 10 000 people (attack rate ratio: 1.13; 95% CI: 1.01–1.27).

Although we only implemented the vaccination campaign after the epidemic peaked in the Bauleni township, the campaign preceded the corresponding peaks in the other nine targeted towns (Fig. 1).

Discussion

In 10 apparently high-risk townships in Lusaka the vaccinators administered over 420 000 doses of oral cholera vaccine, resulting in over 70% of the target population being vaccinated. Box 1 summarizes the major achievements and lessons learnt from the campaign. Such mass campaigns appear to be

| Age (years) | Target population | No. of vaccines (% in age group) | Administrative coverage, % |
|------------|-------------------|---------------------------------|---------------------------|
|            |                   | First phase | Catch-up | Total |
| 1–5        | 78 189            | 75 725 (92.0) | 6609 (8.0) | 82 334 | 105.3 |
| 5–15       | 144 652           | 163 612 (91.7) | 14 839 (8.3) | 178 451 | 123.4 |
| >15        | 355 202           | 313 942 (88.0) | 31 373 (19.2) | 345 315 | 46.0 |
| All        | 578 043           | 371 279 (67.5) | 52 821 (21.5) | 424 100 | 73.4 |

* Estimates based on the 2016 projection of the results of the 2010 national census.

Table 1. Numbers of vaccines in each age group and each phase of the single-dose vaccination campaign against cholera and overall administrative coverages, Lusaka, Zambia, 2016

Ethics

The vaccination campaign was conducted as part of the public health response to the cholera outbreak and was approved by the Zambian Ministry of Health.

Results

Administrative coverage

Between 9 and 25 April 2016, 424 100 vaccine doses were administered to an estimated combined target population of 578 043, giving an estimated administrative coverage of 73.4%. Estimated administrative coverage in the targeted townships varied between 61.9% and 105.8% (Fig. 2).

Of the doses that vaccination teams administered, 371 279 (87.5%) were administered during the first phase – i.e. at the static sites – and the rest during the catch-up at mobile sites (Table 1). Although most of the doses used in the catch-up phase were used on adults, estimated administrative coverage remained generally higher in children than in adults (Table 1).

Performance indicators

At each of the static sites, the vaccination team administered cholera vaccine to a mean of 2256 (range: 306–5843) people per day, i.e. to about half of the target of 5500. The corresponding number for the mobile sites was even lower: 1492 (range: 371–3757).

Vaccine wastage was less than 0.01% (459/424 100). At the end of the campaign, 174 031 doses remained in the cold room and were retained for possible use as second doses. There were no reports of doses being discarded because of invalid vaccine vial monitors.

Costs

Of the total cost of the vaccination campaign, which was US$78 614 United States dollars (US$), US$78 483 (80.2%) were used on vaccine procurement (Table 2). Local delivery cost was US$173 677, that is, a mean of just US$0.41 per dose administered.

Outbreak characteristics

During the entire 2016 cholera outbreak in Lusaka, which ran between epidemiological week 5 and week 24, the health ministry reported 1139 confirmed and/or suspected cholera cases (Fig. 1). Over the same period, the ministry recorded 20 cholera-related deaths, of which 10 occurred in community settings and 10 in health facilities. These 20 deaths represent 1.76% of the confirmed and/or suspected cholera cases that were reported. The weekly incidence of cases peaked in epidemiological week 12, when 150 suspected cases were reported. In Lusaka, the overall attack rate was 4.89 per 10 000 people. Attack rates were significantly higher among children younger than five years than among older individuals: 5.80 vs 4.71 per 10 000 people (attack rate ratio: 1.23; 95% CI: 1.06–1.42). They were also significantly higher among males than among females: 5.20 vs 4.59 per 10 000 people (attack rate ratio: 1.13; 95% CI: 1.01–1.27).

Although we only implemented the vaccination campaign after the epidemic peaked in the Bauleni township, the campaign preceded the corresponding peaks in the other nine targeted towns (Fig. 1).
feasible within large urban settings. When, in 2016, the health ministry found itself faced with the threat of a major outbreak of cholera in Lusaka, it had no previous experience with vaccination campaigns against the disease. However, after careful review of the available literature, particularly the then-unpublished results of the single-dose reactive campaign organized in South Sudan, the health ministry took the decision to use a single-dose strategy. This was because insufficient vaccine doses were available to follow the more usual, two-dose regimen. The possibility of delivering a second dose at a later stage, once adequate doses of vaccine became available, was discussed during the planning phase. Using a combination of new stock and the doses leftover from the single-dose campaign, the health ministry administered second doses on 16–21 December 2016, i.e. before the 2016/2017 rainy season. Since then, single-dose campaigns based on oral cholera vaccine have taken place in Haiti and Mozambique.

In April 2017, WHO’s Strategic Advisory Group of Experts on immunization updated its recommendations on the use of oral cholera vaccine, stating that “a single dose strategy could be considered in areas experiencing cholera outbreaks. Considering the limited evidence about the duration of protection, additional doses might be needed to ensure longer-term protection.”

In reactive mass immunizations, a speedy response is needed if a major outbreak is to be prevented. In Lusaka in 2016, mass immunization began just 21 days after the decision to vaccinate was made and two months after the appearance of the first reported case. A key step was the rapid detection and declaration of the outbreak by the health ministry. Knowledge of the local cholera epidemiology and good collaboration between the ministry and its international partners allowed the choice of vaccination strategy, the preparation of the request for the vaccine doses from the global stockpile and the import of the released doses to proceed smoothly. This process also allowed vaccinations to begin as soon as the doses reached Lusaka. The cold-chain logistics and vaccine distribution in Lusaka were simpler than those described in some other campaigns, thanks, in part, to the thermostability of the vaccine used.

Although some campaigns based on oral cholera vaccine have reached higher coverages, the overall administrative coverage achieved in Lusaka (73.4%) was similar to that recorded in other urban campaigns. The accuracy of data on administrative coverage is often limited by the use of population estimates, especially when such estimates relate to a large city, such as Lusaka, that has a dynamic population and many informal settlements. During the 2016 vaccination campaign described here, there were xenophobic riots in some of the targeted townships and this unrest may have contributed

| Characteristic | Costs, US$ (% of total) |
|---------------|-------------------------|
| Vaccine purchase* | 784,831 (80.2) |
| International shipment* | 20,106 (2.0) |
| Staff incentives* | 65,922 (6.7) |
| Food, identification cards and other staff expenses* | 105,433 (1.1) |
| Vaccination equipment and consumables | 25,325 (2.6) |
| Social mobilization materials and consumables | 15,252 (1.6) |
| Logistical costs of venue use and waste management | 25,081 (2.6) |
| Transport costs | 31,554 (3.2) |
| Total cost of the campaign† | 978,614 (100) |
| Total local delivery cost† | 173,677 (17.7) |

* The proportion of the total costs, for the 598,131 imported doses, represented by the 424,100 doses that were administered in the single-dose campaign.
† Excluding the administrative costs for, and salaries of, any overseas personnel.
‡ Excluding the costs of monitoring and evaluation.

US$: United States dollars.

Box 1. Major achievements and lessons learnt from Lusaka vaccination campaign, Zambia, 2016

Outcome
- In response to cholera outbreaks, large targeted reactive vaccination campaigns are feasible in large urban settings and can be deployed in a timely manner.
- Given a global shortage of cholera vaccines, a single-dose strategy allows a greater population to be vaccinated. In Lusaka, such a strategy allowed targeting of the entire population in the areas considered most at risk of Vibrio cholerae transmission.
- The per-dose cost of the Zambia campaign, implemented in response to an outbreak, was at least as low as that of campaigns implemented in non-outbreak settings and, since vaccination teams were underused, this could have been reduced.

Implementation
- Factors that allowed a relatively quick decision-making process were: good understanding of the local cholera epidemiology, rapid confirmation and declaration of the outbreak by the health ministry and good collaboration between Médecins Sans Frontières, the health ministry and the World Health Organization in sending the vaccine request to the International Coordination Group early. In addition, the health ministry’s anticipation of regulatory hurdles was a key factor in ensuring that the first use of oral cholera vaccine in Zambia began quickly.
- Use of static vaccination sites was probably a more efficient and cheaper strategy than house-to-house visits.
- Age stratification of the tally-sheet data allowed the catch-up activities to be focused mainly on adults, i.e. the age group that had relatively poor coverage in the first phase of the campaign. The recording on the tally sheets of the sex of each vaccine could have improved such focus on specific low-coverage groups. However, the coverages estimated in most urban campaigns of cholera vaccination indicate that specific approaches to improve coverage among adults, particularly men, should probably be implemented from the onset of any such campaign.
- In Lusaka and, probably, similar large urban settings, the cold chain for an oral cholera vaccine with good thermostability can be simply based on a single cold room for the time of the vaccination campaign.

Table 2. Costs of the single-dose vaccination campaign against cholera, Lusaka, Zambia, 2016
to a lower coverage than initially expected. In Lusaka in 2016, as in several previous vaccination campaigns against cholera,\textsuperscript{8,11,23,25} administrative coverage was much lower among adults than among children (Table 1). Although vaccinee sex was not recorded on the tally sheets, the vaccination teams reported that they vaccinated far fewer men than women at the static sites. While the catch-up campaign made it possible to narrow the gap in coverage between adults and children, coverage among adults, and particularly among men, remained relatively poor. In future similar campaigns, the tailoring of catch-up specifically to benefit women and, particularly, men needs to be carefully considered.

As the mean number of people vaccinated daily at each static site was considerably lower than the set target number, vaccination teams at the sites were generally underused. There was probably, therefore, scope to reduce the mean per-dose cost of the local implementation of the campaign. However, even with the underuse, the mean per-dose cost of local delivery in Lusaka (US$ 0.41) accounted for less than 20% of the total per-dose costs and was lower than the corresponding values previously reported for the Shanchol vaccine. For example, it was lower than the corresponding values reported in India in 2011 (US$ 0.49),\textsuperscript{26} Bangladesh in 2011 (US$ 0.76),\textsuperscript{27} Guinea in 2012 (US$ 0.89),\textsuperscript{28} and South Sudan in 2014 (US$ 0.63).\textsuperscript{29} Between-study comparisons of per-dose costs have to be made with caution, because of the differences in the collection of cost data, estimation of per-dose costs and value of the United States dollar.\textsuperscript{29} The number of people reported with cholera in Lusaka after the single-dose campaign remained limited and the outbreak did not spread within any of the 10 targeted townships even when access to safe drinking water and sanitation remained poor.

This large-scale single-dose campaign, run in a densely populated urban area, showed to be feasible and appeared effective. Given the continuing global shortage of cholera vaccines, the use of single doses of oral cholera vaccine will remain an important alternative vaccine-delivery strategy in future cholera epidemics.

Acknowledgements
We thank Timothy Fox, Jean-Guy Audoud and Cecile Barrier.

Competing interests: None declared.

Newborns were vaccinated with a single dose of Shanchol vaccine, from a fixed site, in an investment-based cover. To the best of our knowledge, there is no evidence of the future need for a booster dose. However, a booster dose could be given as an injection with the first dose of a second campaign to consolidate immunity.

We thank Dr. Sanjiv Sharma, Head of the National Institute of Cholera and Enteric Fever, for his continuous support and for helping to coordinate the vaccination campaign. We also thank Pauline Greene and Cecile Barrier for their comprehensive follow-up and for sharing data from the field. We also thank the Zambian government, particularly the Ministry of Health and the District Health Management Teams, for their support and collaboration during the vaccination campaign. We are grateful to all field workers and community volunteers who made the vaccination campaign possible.

We thank the Ministry of Health and the District Health Management Teams for their support and collaboration during the vaccination campaign. We are grateful to all field workers and community volunteers who made the vaccination campaign possible.

The authors acknowledge the U.S. National Institute of Allergy and Infectious Diseases (NIAID) for funding this project through a grant for research. They also thank the Ministry of Health and Social Services of Zambia for their support and collaboration during the vaccination campaign. The authors also thank all field workers and community volunteers who made the vaccination campaign possible. They are grateful to the Ministry of Health and Social Services of Zambia for their support and collaboration during the vaccination campaign.

Xiaomei Zhang, Susanna Colombo, and Fadewa Al-Atsma for their assistance in data collection and analysis. We also thank all field workers and community volunteers who made the vaccination campaign possible. They are grateful to the Ministry of Health and Social Services of Zambia for their support and collaboration during the vaccination campaign.
Resumen

Investigaciones sobre la aplicación: vacunación masiva reactiva con una sola dosis de vacuna oral contra el cólera en Zambia

Objetivo describir la aplicación y la viabilidad de una estrategia innovadora de vacunación masiva, basada en una vacuna oral contra el cólera de una sola dosis, para frenar una epidemia de cólera en un entorno urbano grande.

Método en abril de 2016, en las primeras etapas de un brote de cólera en Lusaka, Zambia, el Ministerio de Salud colaboró con Médecins Sans Frontières y la Organización Mundial de la Salud para organizar una campaña de vacunación de masa fundada en una vacuna anticholérica oral a dosis única. En el contexto de una pandemia de cólera, la aplicación de una vacuna oral a dosis única puede ser un enfoque innovador y efectivo para controlar la epidemia. El objetivo de esta investigación es describir la aplicación y la viabilidad de esta estrategia en Zambia.

Resultados En general, los equipos de vacunación administraron 424.100 dosis de la vacuna a una población objetivo de unos 578.043 habitantes, lo que resultó en una cobertura administrativa estimada del 73.4%. Después de la campaña, se registraron pocos casos de cólera y no hubo pruebas de propagación de la enfermedad dentro de las zonas vacunadas. El costo total de la campaña (2,31 dólares estadounidenses (USD) por dosis) incluyó el costo relativamente bajo de la entrega local – 0,41 USD por dosis. Conclusion se descubrió que una campaña reactiva dirigida y en gran escala con una vacuna oral de dosis única, organizada en respuesta a una epidemia de cólera, es factible y efectiva. Sin embargo, es importante considerar la maximización del número de vacunados en respuesta a una epidemia de cólera, mediante el uso de una sola dosis por miembro de una comunidad en riesgo.
References

1. Cholera. Fact sheet. Updated October 2016 [Internet]. Geneva: World Health Organization; 2016. Available from: http://www.who.int/mediacentre/factsheets/fs107/en/ [cited 2017 Jun 23].

2. Cholera. 2015. Wkly Epidemiol Rec. 2016 Sep 23;29(38):433–40. PMID: 27665620.

3. Legros D, Paquet C, Perea W, Marty J, Mugisha NK, Royer H, et al. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. Bull World Health Organ. 1999;77(10):837–42. PMID: 10593032.

4. Porta ML, Lenglet A, de Weerdt S, Crestani R, Sirene R, Frawley MJ, et al. Feasibility of a preventive mass vaccination campaign with two doses of oral cholera vaccine during a humanitarian emergency in South Sudan. Trans R Soc Trop Med Hyg. 2014 Dec;108(12):810–5. doi: http://dx.doi.org/10.1099/trstmh.0153. PMID: 25317198.

5. Martin S, Lopez AL, Bellos A, Deen J, Ali M, Alberti K, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ. 2014 Dec 1;92(12):881–93. doi: http://dx.doi.org/10.2471/BLT.14.139949. PMID: 25527272.

6. Phares CR, Date K, Travers P, Déglise C, Wongjindanon N, Ortega L, et al. The effectiveness of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med. 2016 May 5;374(18):1723–32. doi: http://dx.doi.org/10.1056/NEJMoai1510330. PMID: 27144684.

7. Hsiao A, Desai SN, Mogasale V, Excler J-L, Digilio L. Lessons learnt from deploying 12 oral cholera vaccine campaigns in resource-poor settings. Bull World Health Organ. 2018;96:86–93.

8. Bi Q, Ferreras E, Pezzoli L, Legros D, Ivers LC, Date K, et al.; Oral Cholera Vaccine Working Group of The Global Task Force on Cholera Control. Protection against cholera from killed whole-cell oral cholera vaccine: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Oct;17(10):1080–8. doi: http://dx.doi.org/10.1016/S1473-3099(17)30339-6. PMID: 28729167.

9. Desai SN, Pezzoli L, Martin S, Costa A, Rodrigo C, Legros D, et al. A second oral cholera vaccine campaign in a refugee camp, Thailand. Vaccine. 2016 Jan 2, 29(1):128–33. doi: http://dx.doi.org/10.1016/j.vaccine.2015.10.112. PMID: 26593635.

10. Martin S, Costa A, Perea W, Stockpiling oral cholera vaccine. Bull World Health Organ. 2012 Oct 1;90(10):714. doi: http://dx.doi.org/10.2471/BLT.12.112433. PMID: 23109735.

11. Parker LA, Rumunu J, Jamet C, Kenyi Y, Lino RL, Wamala JF, et al. Population and Demographic Projections 2011–2035 [Internet]. Population and Demographic Projections-2011-2035 [cited 2017 Jun 27].

12. Luquero FJ. Time series analysis: defining a cholera intervention threshold for Lusaka. Paris: Epicentre; 2012.

13. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea. 2012. PLoS Negl Trop Dis. 2013 10;7(10):e2465. doi: http://dx.doi.org/10.1371/journal.pntd.0002465. PMID: 24174164.

14. Car SK, Sah B, Patnaik B, Kim HY, Kenkettas A, Shin S, et al. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis. 2014 Feb 6;8(2):e2629. doi: http://dx.doi.org/10.1371/journal.pntd.0002629. PMID: 24516675.

15. Luquero FJ. Vaccine effectiveness of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med. 2016 May 5;374(18):1723–32. doi: http://dx.doi.org/10.1056/NEJMoai1510330. PMID: 27144684.